Source comparison
Post-Surgery Patients Researching BPC-157: Comparison Table
Standard post-op protocol (rest, elevation, compression) Reduces inflammation and infection risk; allows baseline healing 3–6 weeks for soft tissue, 8–12 weeks for bone Standard of care All surgical recoveries Essential foundation. Non-negotiable baseline rega
This comparison does not assign a generated winner or score.
- Standard post-op protocol (rest, elevation, compression)
- Reduces inflammation and infection risk; allows baseline healing
- 3–6 weeks for soft tissue, 8–12 weeks for bone
- Standard of care
- All surgical recoveries
- Essential foundation. Non-negotiable baseline regardless of adjunct therapies
- Platelet-rich plasma (PRP) injection
- Delivers concentrated growth factors from autologous blood to injury site
- 4–8 weeks for soft tissue response
- FDA-cleared devices for preparation; off-label use for most indications
- Tendon, ligament, cartilage injuries
- Established clinical use with modest efficacy; expensive ($500–$2,000 per session)
- BPC-157 peptide administration
- Upregulates VEGF, increases GH receptor density, stimulates fibroblast proliferation
- Animal models: 40–60% faster wound closure
- Research compound. Not FDA-approved for human use
- Investigational use in soft tissue repair contexts
- Strongest preclinical data; zero human trials; sourcing and purity highly variable
- Hyperbaric oxygen therapy (HBOT)
- Increases dissolved oxygen in plasma, enhancing fibroblast activity and angiogenesis
- 10–20 sessions over 2–4 weeks
- FDA-approved for specific wound types (diabetic ulcers, radiation injury)
- Non-healing wounds, compromised tissue perfusion
- Established for select indications; requires clinical facilities; $200–$400 per session